C4 Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $6,463 | $7,238 | $5,177 | $15,362 |
Gross Profit | 7,238 | 3,411 | 13,306 | |
EBITDA | -28,501 | -28,708 | -32,676 | -22,610 |
EBIT | -29,164 | -34,442 | -24,666 | |
Net Income | -26,020 | -26,322 | -34,573 | -24,666 |
Net Change In Cash | 6,463 | 7,238 | 5,177 | 15,362 |
Free Cash Flow | -12,242 | -33,285 | -17,928 | -24,120 |
Cash | 78,157 | 51,293 | 55,499 | 59,649 |
Basic Shares | 71,006 | 70,833 | 70,606 | 69,627 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $35,584 | $20,756 | $31,096 | $45,785 |
Gross Profit | 35,584 | -96,950 | 23,524 | 42,878 |
EBITDA | -103,367 | -122,103 | -124,283 | -78,840 |
EBIT | -105,185 | -129,840 | -131,855 | -81,747 |
Net Income | -105,316 | -132,493 | -126,499 | -86,037 |
Net Change In Cash | 35,584 | 20,756 | 31,096 | 45,785 |
Cost of Revenue | -46,370 | -104,901 | ||
Free Cash Flow | -65,337 | -108,546 | -111,435 | -88,242 |
Cash | 55,499 | 126,590 | 29,754 | 76,124 |
Basic Shares | 69,370 | 49,640 | 48,861 | 46,041 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.37 |
2025-03-31 | -$0.37 |
2024-12-31 | -$0.49 |
